1011 related articles for article (PubMed ID: 19912682)
1. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
[TBL] [Abstract][Full Text] [Related]
2. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
Pattullo V; Ravindran NC; Mazzulli T; Wong DK; Heathcote EJ
J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
5. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
6. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
7. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Aziz H; Raza A; Waheed Y; Gill U; Gill ML
Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
[TBL] [Abstract][Full Text] [Related]
8. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
9. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
10. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
[TBL] [Abstract][Full Text] [Related]
12. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
[TBL] [Abstract][Full Text] [Related]
13. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.
Fried MW; Hadziyannis SJ; Shiffman ML; Messinger D; Zeuzem S
J Hepatol; 2011 Jul; 55(1):69-75. PubMed ID: 21145856
[TBL] [Abstract][Full Text] [Related]
14. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
[TBL] [Abstract][Full Text] [Related]
15. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.
Dogan UB; Akin MS; Yalaki S
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1317-20. PubMed ID: 23680912
[TBL] [Abstract][Full Text] [Related]
16. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
Zhou YQ; Wang XH; Hong GH; Zhu Y; Zhang XQ; Hu YJ; Mao Q
J Viral Hepat; 2011 Aug; 18(8):595-600. PubMed ID: 21105968
[TBL] [Abstract][Full Text] [Related]
17. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
18. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
Fabris P; Carlotto A; Del Bianco T; Malfatti F; Tramarin A; Miotti MA; Baldo V; Floreani A; Giordani MT; Grasso A
Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1396-401. PubMed ID: 23743559
[TBL] [Abstract][Full Text] [Related]
19. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
20. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
Dogan UB; Atabay A; Akin MS; Yalaki S
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1082-5. PubMed ID: 23524524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
